🇺🇸 FDA
Patent

US 11377444

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

granted A61PA61P35/00

Quick answer

US patent 11377444 (Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors) held by Medshine Discovery Inc. expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00